January 29, 2019
University of North Carolina Lineberger Comprehensive Cancer Center scientist Antonio “Tony” Amelio, PhD, is not necessarily looking for the “smoking gun” of cancer biology, or one single cause of cancer. Instead, he’s looking into how a family of newly described proteins involved in the cellular stress response can cause a complex ripple effect of changes …
January 24, 2019
In preliminary findings presented at the 2018 San Antonio Breast Cancer Symposium, researchers led by UNC Lineberger's Charles M. Perou, PhD, and Susana Garcia-Recio, PhD, reported they found increased expression of the gene FGFR4 in metastatic breast cancer tumors.
January 16, 2019
Though he aspired for a career in marine biology, UNC Lineberger’s Hector L. Franco, PhD, discovered the field genetics at college, which led him to change his academic focus and earn a doctorate in biochemistry and molecular genetics.
January 16, 2019
In March of 2011, when she was 14 years old, Lily Newton was diagnosed with a rare cancer of the bone and soft tissue called Ewing sarcoma. Cancer changed Newton’s life in more ways than she could have imagined.
January 10, 2019
Decorated military veteran MG Autry says service to others is central to his life. Even when he is facing his own health challenges, he would have it no other way.
January 8, 2019
"The Art of Science and Innovation," an exhibit at the North Carolina Museum of Art, featured images by UNC Lineberger Comprehensive Cancer Center researchers.
January 3, 2019
UNC Lineberger leaders recently hosted the annual research symposium on geriatric oncology, which is the field of medicine that deals with diagnosis and treatment of cancer for adults 65 years and older.
January 2, 2019
UNC Lineberger Comprehensive Cancer Center’s faculty were at the forefront of a many new efforts to fight, prevent and understand cancer in 2018. Projects launched or completed in the year included efforts to use the immune system to fight cancer, to better prevent cancer through screening, and to understand the disease at the most basic …
December 21, 2018
UNC Lineberger’s Joshua Zeidner, MD, reported preliminary data at the 60th American Society of Hematology Annual Meeting from a phase II clinical trial for administering a high-dose of the chemotherapy treatment cytarabine followed by an immune checkpoint inhibitor, pembrolizumab, in patients with acute myeloid leukemia that had relapsed or no longer responded to other treatment.
December 20, 2018
At the 60th American Society of Hematology Annual Meeting in San Diego on Dec. 3, Eben Lichtman, MD, presented preliminary findings from preclinical studies of CAR T-cells directed towards a potential target called B7-H3, which is found on the cell surface of certain types of AML.
